Boston Scientific Pauses Enrollment In Farapulse Study In Drug-Naive Patients With Irregular Heart Rhythm
Portfolio Pulse from Vandana Singh
Boston Scientific has paused enrollment in its AVANT GUARD trial for the FARAPULSE Pulsed Field Ablation System in drug-naive patients with persistent atrial fibrillation due to unanticipated observations. The trial aims to evaluate the system as a first-line treatment compared to anti-arrhythmic drug therapy. The pause is temporary, and the company remains confident in the system's performance.
October 23, 2024 | 11:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Boston Scientific has temporarily paused the AVANT GUARD trial for its FARAPULSE system in drug-naive AFib patients due to unexpected observations. The company remains confident in the system's performance, and the pause is not due to life-threatening issues.
The pause in the trial could lead to short-term uncertainty and a negative impact on BSX's stock price. However, the company's confidence in the system and the non-life-threatening nature of the observations may mitigate long-term concerns.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100